| Gregory D Pfennig, NP | |
|
520 Chautauqua Blvd, Valley City, ND 58072-3145 | |
| (701) 845-6000 | |
| (701) 845-6150 |
| Full Name | Gregory D Pfennig |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 20 Years |
| Location | 520 Chautauqua Blvd, Valley City, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932126414 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | R28569 (North Dakota) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | R28569 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Medical Center Fargo | 8426967803 | 1094 |
News Archive
To honour its 60th anniversary this year, ASICS took its expertise in running to another level by conducting an unprecedented research into the mind of the runner. Executed by the research institute Synovate, ASICS' 'Reasons to Run' research asked more than 3,500 runners in seven European countries* to reveal the 'why?' behind their actions, making it the biggest study of its kind ever.
Idera Pharmaceuticals, Inc. today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.
Screening appears to reduce mortality due to ovarian cancer, according to the results of The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial published in the Lancet yesterday.
Scientists at Aberdeen's Rowett Research Institute have shown that a very low carbohydrate weight-loss diet results in a four-fold reduction in the numbers of certain types of bacteria in the gut of obese men.
As the number of swine flu cases now confirmed in Australia edges close to 900, neighbour Singapore has issued advice warning its residents not to travel to Victoria the state worst-hit by the outbreak of influenza A H1N1 with 752 cases.
› Verified 2 days ago
| Entity Name | Sanford Clinic North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241351 PECOS PAC ID: 4284546151 Enrollment ID: O20031112000221 |
News Archive
To honour its 60th anniversary this year, ASICS took its expertise in running to another level by conducting an unprecedented research into the mind of the runner. Executed by the research institute Synovate, ASICS' 'Reasons to Run' research asked more than 3,500 runners in seven European countries* to reveal the 'why?' behind their actions, making it the biggest study of its kind ever.
Idera Pharmaceuticals, Inc. today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.
Screening appears to reduce mortality due to ovarian cancer, according to the results of The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial published in the Lancet yesterday.
Scientists at Aberdeen's Rowett Research Institute have shown that a very low carbohydrate weight-loss diet results in a four-fold reduction in the numbers of certain types of bacteria in the gut of obese men.
As the number of swine flu cases now confirmed in Australia edges close to 900, neighbour Singapore has issued advice warning its residents not to travel to Victoria the state worst-hit by the outbreak of influenza A H1N1 with 752 cases.
› Verified 2 days ago
| Entity Name | Sanford Medical Center Fargo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
To honour its 60th anniversary this year, ASICS took its expertise in running to another level by conducting an unprecedented research into the mind of the runner. Executed by the research institute Synovate, ASICS' 'Reasons to Run' research asked more than 3,500 runners in seven European countries* to reveal the 'why?' behind their actions, making it the biggest study of its kind ever.
Idera Pharmaceuticals, Inc. today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.
Screening appears to reduce mortality due to ovarian cancer, according to the results of The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial published in the Lancet yesterday.
Scientists at Aberdeen's Rowett Research Institute have shown that a very low carbohydrate weight-loss diet results in a four-fold reduction in the numbers of certain types of bacteria in the gut of obese men.
As the number of swine flu cases now confirmed in Australia edges close to 900, neighbour Singapore has issued advice warning its residents not to travel to Victoria the state worst-hit by the outbreak of influenza A H1N1 with 752 cases.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gregory D Pfennig, NP 520 Chautauqua Blvd, Valley City, ND 58072-3145 Ph: (701) 845-6000 | Gregory D Pfennig, NP 520 Chautauqua Blvd, Valley City, ND 58072-3145 Ph: (701) 845-6000 |
News Archive
To honour its 60th anniversary this year, ASICS took its expertise in running to another level by conducting an unprecedented research into the mind of the runner. Executed by the research institute Synovate, ASICS' 'Reasons to Run' research asked more than 3,500 runners in seven European countries* to reveal the 'why?' behind their actions, making it the biggest study of its kind ever.
Idera Pharmaceuticals, Inc. today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.
Screening appears to reduce mortality due to ovarian cancer, according to the results of The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial published in the Lancet yesterday.
Scientists at Aberdeen's Rowett Research Institute have shown that a very low carbohydrate weight-loss diet results in a four-fold reduction in the numbers of certain types of bacteria in the gut of obese men.
As the number of swine flu cases now confirmed in Australia edges close to 900, neighbour Singapore has issued advice warning its residents not to travel to Victoria the state worst-hit by the outbreak of influenza A H1N1 with 752 cases.
› Verified 2 days ago
Kari Marie Kietzman, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 520 Chautauqua Blvd, Valley City, ND 58072 Phone: 701-845-6000 Fax: 701-845-6150 | |
Sarah Ellen Hansen, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 132 4th Ave Ne, Valley City, ND 58072 Phone: 701-845-8060 | |
Stacie Cleveland, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 367 2nd St Nw, Valley City, ND 58072 Phone: 701-845-6550 | |
Trent William Bitz, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 132 4th Ave Ne, Valley City, ND 58072 Phone: 701-845-8060 | |
Leah Kathryn Swenson, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 132 4th Ave Ne, Valley City, ND 58072 Phone: 701-845-8060 Fax: 701-845-8067 | |
Dr. Joann Delane Trader, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 520 Chautauqua Blvd, Valley City, ND 58072 Phone: 701-845-6000 |